Talaris Therapeutics, Inc. (TALS)
$1.45
Rating:
Recommendation:
-
| Symbol | TALS |
|---|---|
| Price | $1.45 |
| Beta | 0.000 |
| Volume Avg. | 0.21M |
| Market Cap | 60.149M |
| Shares () | - |
| 52 Week Range | 0.89-10.56 |
| 1y Target Est | - |
| DCF Unlevered | TALS DCF -> | |
|---|---|---|
| DCF Levered | TALS LDCF -> | |
| ROE | -31.84% | Strong Sell |
| ROA | -33.70% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 5.99% | Neutral |
| P/E | - | |
| P/B | 0.31 | Neutral |
Latest TALS news
About
Download (Excel)Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.